Oncobit is proud to partner with TrilliumBiO, a biomarker discovery company specializing in the development and commercialization of novel diagnostic tests. This partnership will not only broaden access to Oncobit's uveal melanoma solution for U.S patients but also improve patient management by integrating diagnostic insights with emerging therapies.

We are excited to announce that Oncobit has successfully completed a capital increase of more than CHF 1.9 million. This round was supported by both existing and new investors, including private business angels and the strategic investor ID Solutions (IDS). We are grateful for the continued trust and commitment of our shareholders and partners who share our mission to make precision cancer monitoring broadly accessible. The funding further strengthens our financial position and enables us to advance our clinical validation, regulatory, and commercialization efforts, as well as expand into additional cancer indications and new markets.

We are proud to announce our successful recertification of ISO 13485, and the expansion of our IVDR certification to cover additional indications.

We are excited to welcome Prof. Reinhard Dummer to Oncobit as Senior Medical Advisor. Prof. Dummer is a highly cited Professor of Dermatology at the University Zurich. He is renowned for his extensive contributions to skin cancer research, particularly in melanoma and non-melanoma skin cancers at the University Hospital Zurich. As Senior Medical Advisor, Prof. Dummer will play a key role in guiding Oncobit’s clinical strategies, and fostering collaborations with leading medical institutions and industry partners.

We are thrilled to announce that we closed a 1.5M CHF Pre-Series A Financing round. A huge thank you to our existing and new investors for supporting our vision of enabling personalized cancer care. The investment will enable us to continue to grow and strengthen our position in the cancer monitoring market.

Oncobit, a pioneer in precision cancer monitoring solutions, is pleased to announce changes to its Board of Directors. With the achievement of CE marking for our products and first revenues in Europe, the company focus shifts from product validation to clinical and commercial expansion. Following this shift the changes to the board composition, pave the way for the company’s future success. The whole Oncobit team extends heartfelt gratitude to Dr. Tomas Hruz for his invaluable contributions in the areas of bioinformatic analyses and intellectual property and warmly welcomes Prof. Mitch Levesque and Bram Goorden, MBA as new members.

We are pleased to announce that we received the In Vitro Diagnostic Regulation (IVDR) certification for our Oncobit PM melanoma test suite, which allows us to CE-mark these tests and to offer them for clinical use. Oncobit PM is designed to detect specific cancer markers in the tumor-derived fraction of circulating cell-free DNA (ctDNA) isolated from the blood of melanoma patients. Oncobit PM tests detect specific cancer hot spot mutations in the genes BRAF, NRAS, GNAQ, GNA11, and SF3B1, critical for cutaneous and uveal melanoma.

We are proud to share that our Oncobit™ PM ctDNA analysis tests are now in use at three prominent cancer centers across Germany, including the University Medical Center Hamburg-Eppendorf (UKE) led by Prof. Christoffer Gebhardt and the Hauttumorcentrum Charité (HTCC) Charité under the guidance of Prof. Thomas Eigentler. Our advanced Oncobit PM tests play a pivotal role in addressing various issues related to cancer monitoring. Specifically, these esteemed institutions will utilize our tests to generate crucial clinical utility data. This data will not only contribute to the advancement of medical knowledge, but will also enhance patient care by providing valuable insights into cancer management. By establishing our test at these leading study sites, we are pushing the boundaries of cancer research and treatment strategies. Together with UKE Hamburg and the Hauttumorcentrum Charité (HTCC), we're committed to making a positive impact on patient outcomes and contributing to the future of personalized medicine.

We are thrilled to announce that we have signed a service agreement with Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. This collaboration aims to improve the use and understanding of circulating tumor DNA (ctDNA) analysis as a reliable and real time therapy response marker in clinical trials.

We are delighted to announce that Oncobit is collaborating with the National Cancer Institute (NCI) on the BIOMELKID trial. Our joint mission: To identify predictive and prognostic biomarkers in metastatic melanoma patients undergoing immunotherapy. Professor Vincas Urbonas and his team at the NCI are leading this impactful project focused on the study of ctDNA in melanoma patients. With our Oncobit PM digital PCR solutions, we are pleased to provide a powerful tool to reliably quantify ctDNA. Our shared goal is to unlock the secrets of circulating tumor DNA to better understand disease progression and treatment response. Aiming to improve patient care!